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A comparative phosphoproteomic analysis
of a human tumor metastasis model using
a label-free quantitative approach
Alterations in cellular phosphorylation patterns have been implicated in a number of
diseases, including cancer, through multiple mechanisms. Herein we present a survey of
the phosphorylation profiles of an isogenic pair of human cancer cell lines with opposite
metastatic phenotype. Phosphopeptides were enriched from tumor cell lysates with
titanium dioxide and zirconium dioxide, and identified with nano-LC-MS/MS using an
automatic cross-validation of MS/MS and MS/MS/MS (MS21MS3) data-dependent
neutral loss method. A spectral counting quantitative strategy was applied to the two cell
line samples on the MS2-only scan, which was implemented successively after each
MS21MS3 scan in the same sample. For all regulated phosphopeptides reported by
spectral counting analysis, sequence and phosphorylation site assignments were vali-
dated by a MS21MS3 data-dependent neutral loss method. With this approach, we
identified over 70 phosphorylated sites on 27 phosphoproteins as being differentially
expressed with respect to tumor cell phenotype. The altered expression levels of proteins
identified by LC-MS/MS were validated using Western blotting. Using network pathway
analysis, we observed that the majority of the differentially expressed proteins were
highly interconnected and belong to two major intracellular signaling pathways. Our
findings suggest that the phosphorylation of isoform A of lamin A/C and GTPase acti-
vating protein binding protein 1 is associated with metastatic propensity. The study
demonstrates a quantitative and comparative proteomics strategy to identify differential
phosphorylation patterns in complex biological samples.
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1 Introduction
Breast cancer is by far the most frequent cancer of women,
with an estimated 192 370 new cases and 40 170 deaths in
the United States in 2009. The majority of cancer mortality
is attributed to metastasis, which is the spread of tumor cells
to a secondary site such as bone, lung, and liver. The
multistep nature of metastasis poses difficulties in both
design and interpretation of experiments to unveil the
mechanisms causing the process. Studies on excised fixed
human tissues are complicated by the variance of
genetic background between individuals and by the
cellular heterogeneity of a complex tissue mass [1]. Through
in vivo selection of monoclonal cultures of the MDA-MB-435
breast tumor cell line we were able to characterize
a pair of subclones (M-4A4 and NM-2C5), which differ in
their ability to complete the metastatic process [2–4]. When
orthotopically inoculated into athymic mice, both cell lines
form primary tumors, but only M-4A4 is capable of
metastasis to the lungs and lymph nodes. These cell lines
constitute a valuable model for the study of cancer
metastasis.
M-4A4 and NM-2C5 have been extensively compared
using gene and protein expression analysis identifying
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[1–3, 5, 6]. However, because protein phosphorylation-
mediated signaling networks regulate much of the cellular
response to external stimuli, and dysregulation in these
networks has been linked to multiple disease states includ-
ing cancer [7], similar studies at the phosphoprotein level
may add valuable biological insight to inhibit the metastatic
process.
Although significant advances have been made over the
past decade to enable the analysis and quantification of
cellular protein phosphorylation events, comprehensive
quantitative analysis of the phosphoproteome is still lacking.
Several MS-based quantification methods have been imple-
mented for phosphoproteomics, including stable-isotope
labeling through chemical modification of peptides with, for
example, isobaric tags for relative and absolute quantitation
and stable-isotope labeling of amino acids in cell culture.
The well-known limitations of label based-methods include
increased complexity of the experimental protocols and the
high cost of reagents.
In recent years, label-free quantitation methods have
received increased attention as promising alternatives that
automatically avoid some of the disadvantages of using stable
isotope labeling methods. One approach is based on calcu-
lating extracted ion chromatogram ratios of peptides from
separate LC-MS experiments and often includes an additional
normalization step. Furthermore, the simple and straightfor-
ward spectral counting approach, in which total numbers of
acquired MS/MS (MS2) spectra assigned to peptides are used
as a read-out, transforms the frequency by which a peptide is
identified into a measure for peptide abundance. Spectral
counts of peptides associated with a protein are then averaged
into a protein abundance index [8]. This approach was recently
employed as a semi-quantitative measure of phosphoprotein
abundance [9, 10]. Although conceptually simple, recent
studies have demonstrated that spectral counting can be as
sensitive as ion peak intensities in terms of detection range
while retaining linearity [11].
Despite published examples of using spectral counting
in quantitative phosphoproteomics, there are still challenges.
In a relatively large-scale phosphorylation study, especially
for phosphoserine and phosphothreonine (pT), there is the
frequent and often overwhelming domination of phosphor-
ylation-specific neutral losses (NLs) in MS2 spectra. These
peaks reduce the intensity of backbone b- and y-type ions that
are critical for both phosphopeptide identification and precise
site localization. To address this issue, a new data-dependent
neutral loss MS/MS/MS (MS3) method that consists of
additional fragmentation of the product of the precursor NL
in the form of an MS3 scan has been introduced. This
approach (MS21MS3 scan) has now been widely adopted for
phosphorylation identification analysis and is especially used
on low mass accuracy mass spectrometers [12, 13]. However,
this strategy requires additional cycle time on the instrument
and therefore reduces the number of spectra that can be
measured in the same amount of time, so that the spectral
counting method is often employed using the MS2-only
scan. Sequence and phosphorylation site assignments are
often manually validated for the phosphopeptides reported by
the MS2 scan, where spectra are checked for the presence of
NL peak(s), coverage of the phosphorylation site by b- and
y-ions, and alternative phosphorylation sites in the sequence
matching the same spectrum [14]. This process is time-
consuming and laborious.
In this report, we present a survey of phosphorylation
profiles for an isogenic pair of human breast cancer cell
lines and describe a general integrated framework for
quantifying enriched phosphoproteins in the two cell lines
by combining automatic validation of the MS21MS3 scan
for phosphopeptide identification, with a subsequent
MS2-only scan for spectral counting. The regulated phos-
phorylated peptides and sites identified by MS2 scan were
validated by the MS21MS3 NL method. Application of the
label-free approach to this source material revealed a panel
of differentially expressed phosphoproteins, which implicate
specific signaling pathways as being associated with distinct
cellular phenotypes.
2 Materials and methods
2.1 Materials
Titanium dioxide (TiO2) (3 mm, 300 Å, part number
MTIO3000) and zirconium dioxide (ZrO2) (3 mm, 300 Å,
part number MZRO3000) were purchased from Glygen
(Glygen, Columbia, MD, USA). Protease inhibitor cocktail
and phosphatase inhibitor cocktail were from Roche (Roche,
Nutley, NJ, USA). Sequencing grade modified trypsin
was from Promega (Promega, Madison, WI, USA). All
other chemicals were from Sigma (Sigma, St. Louis, MO,
USA).
2.2 Cell culture
Human tumor cell lines M-4A4 and NM-2C5 were derived
from the tumor cell line MDA-MB-435 as described
previously [2, 3]. Cell lines were maintained as subconfluent
monolayer cultures in RPMI 1640 medium (Gibco-BRL,
New York, NY, USA) supplemented with 10% fetal calf
serum at 371C under 5% CO2/95% air. Cell lines were
maintained in parallel cultures and harvested using non-
trypsin cell dissociation as cultures reached 75%
confluency. Harvested cells were washed once in serum-
free media and immediately snap-frozen in liquid nitrogen.
2.3 Enrichment of phosphopeptides
TiO2 and ZrO2 particles were pretreated with 30% ACN,
0.1% TFA, and 50% ACN, 10% acetic acid (HAC),
respectively, by vortex for 15 min. After centrifuging at
25 000 g for 5 min, the supernatant was discarded. The pellet
was then treated with 100% ACN. Then TiO2 and ZrO2
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beads were diluted as 20 mg/mL in 30% ACN, 0.1% TFA,
and 50% ACN, 10% HAC separately.
To make cell extracts, a lysis buffer (7 M urea, 2 M
thiourea, 10% glycerol, 2% n-octyl G-D-glucopyranoside,
100 mM DTT, protease inhibitor cocktail, phosphatase
inhibitor cocktail) was directly added to frozen cell pellets
and the lysates were vibrated at room temperature for 1 h.
Cellular debris and other insoluble materials were removed
by centrifuging the mixture at 80 000 g for 1 h. After
measuring protein concentration in each lysate, proteins
were digested with trypsin with a ratio of 50/1 w/w over-
night at 371C.
For enrichment with TiO2, 100 mg tryptic digest of the
lysate was incubated with 50 mL TiO2 beads (20 mg/mL).
After incubation for 30 min with vibration, the TiO2 beads
were first washed with 300 mL 50% ACN, 6% TFA solution,
followed by 300 mL 30% ACN, 0.1% TFA solution twice. The
bound peptides were eluted with 100 mL 10% NH4OH. After
centrifugation, the supernatant was collected and lyophi-
lized to dryness.
For enrichment with ZrO2, 100 mg protein digests were
diluted with 50% ACN, 10% HAC. The sample solution was
mixed with 50 mL ZrO2 beads suspension (20 mg/mL). The
resulting solution was incubated for 30 min at room
temperature. Then the ZrO2 beads were firstly washed with
300 mL 50% ACN, 10% HAC solution, followed by two
washes with 300 mL 10% HAC. The trapped phosphopep-
tides on ZrO2 beads were eluted using 100 mL NH4OH
under sonication for 20 min. After centrifugation, the
supernatant was collected and lyophilized to dryness.
2.4 MS
Dry peptides were suspended in 0.1% formic acid and loaded
for LC-MS/MS analysis in an LTQ mass spectrometer. The
nano-RPLC column (Nano Trap Column 5 mm 200 Å Magic
C18AQ 100 mm 150 mm, Michrom Bioresources, Auburn,
CA, USA) was directly coupled to an LTQ linear IT MS from
Thermo Scientific (Waltham, MA, USA) with a nanospray
source. The LTQ instrument was operated in positive ion
mode. The scan range of each full MS scan was m/z
400–2000. ACN gradients of 5–35% for 70 min at a flow rate
300 nL/min were applied for the separation of phosphopep-
tides. For the detection, the MS was set as a full scan followed
by three data-dependent MS2 events. For MS21MS3 scan, a
subsequent MS3 event was triggered upon detection when an
NL of 49 or 32.7 (loss of H3PO4 for the 12 and 13
charged ions, respectively) was detected among the top ten
most-intense ions in MS2. A dynamic exclusion window was
applied, which prevented the same m/z from being selected
for 1 min after its acquisition. This entire LC-MSn system was
controlled under Xcalibur software 2.0 (Thermo Scientific).
The MS2 and MS3 spectra were searched using
SEQUEST (v0.27) against human IPI database v3.49 with
the following parameters: peptide mass tolerance, 1.5 Da;
MS2 and MS3 fragment ion mass tolerance, 1.4 Da; enzyme
set as trypsin and allowance up to two missed cleavages; no
static modification; dynamic modifications were methionine
oxidation (116 Da), phosphorylation on serine, threonine,
and tyrosine (180 Da); for MS3 data, besides the above
modifications, variable modifications of 18 Da (elimina-
tion of phosphoric acid) on serine and threonine residues
were also selected.
2.5 MS21MS3 scan data analysis
Enriched phosphopeptides were identified with automatic
cross-validation of MS2 and MS3 spectra using the method
of Jiang et al. [15]. Because the charge state of the precursor
ion cannot be determined with low mass accuracy MS, more
than one DTA file with different precursor charge states
(commonly 21 and 31, respectively) were exported for one
tandem spectrum. By combining MS2 spectra and corre-
sponding NL MS3, charge states of precursor ions can be
determined from the m/z value of NL: 49 indicated 12
charged precursor ions, while 32.7 was for 13 charged
ions. Only a DTA spectrum with NL peak of at least 50% of
the base peak in intensity was considered. After removal of
MS2/MS3 pairs with incorrect charge states, MS2 with no
MS3, and MS2/MS3 pairs with NL intensity less than 50%
of the base peak in MS2 spectrum, the remaining MS2 and
MS3 DTA spectra with specific precursor charge states were
searched against the database, respectively. The top ten hit
peptides from a database search for a spectrum were
considered. Then peptide identifications from a pair of
spectra (MS2 and its corresponding MS3) were combined.
Only peptides that were identified from both of the spectra
(MS2 and MS3) were retained. The matched peptide in a
spectra pair with the highest Xcorr’s score was defined as
the top matched peptide for the spectra pair and selected for
filter afterward.
For the determination of phosphorylation sites, Tscore
was introduced as the sum of MS2 and MS3 PTM scores
with the definition as 10 log(P total). For the phospho-
peptide with two or more phosphorylation sites, Tscores of
all candidate sequences with different phosphorylation site
combinations for this phosphopeptide were calculated. Then
the Tscore of a given site was computed by summing the
Tscores of all candidate sequences containing this site.
Phosphorylation sites with top n (equal to the
number of possible phosphorylation sites) Tscores were
considered as the most likely phosphorylation site localiza-
tions [15].
2.6 Spectral counting analysis
We counted the number of spectra observed for each peptide
sequence in an MS run [16]. To calculate a protein spectrum
count, we summed the numbers for all of the peptides
assigned to each protein in that run. We found this
approach preferable to other methods such as parent ion
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peak height because it allowed us to simplify the analysis by
combining all sites on a given protein [9]. Then we applied a
normalized spectral abundance factor (NSAF) approach [17]
to quantify phosphoprotein expression profiles. In spectral
counting, larger proteins are expected to generate more
peptides and therefore more spectral counts than smaller
proteins. Consequently, it is very important to take into
consideration the length or sequence of a protein when
determining protein abundance using spectral counting
[17, 18]. The NSAF approach has at least the same, or better,
capability to capture a wide dynamic range of protein
expression ratios, and it can also identify significantly
expressed proteins via simple statistical tests, such as the
t-test, to compare the mean protein intensities of two or
more samples. The use of the t-test is applicable in this
approach because it has been shown that the log transfor-
mation of the NSAF value is normally distributed. In
addition, the NSAF approach has comparable sensitivity in
identifying differentially expressed proteins as other
approaches based on protein ratios.
After MS2-only scan analysis, the RAW data file was
processed using SEQUEST and validated by Trans-Proteo-
mic Pipeline (TPP). Spectral count data was then extracted
from xml files using an in-house Perl script and output into
Microsoft Excel files. In order to calculate the NSAF value,











where Spc is the number of spectral count, and L is the
length in amino acid for kth protein. The NSAF value was
then natural log-transformed and subjected to independent
two sample t-test using Microsoft Excel. A t-test p value of
less than 0.05 was used to identify significant differentially
expressed phosphoproteins.
2.7 Western blotting
Western blotting was performed using established methods
[19] to confirm the phosphoprotein expression of isoform A
of Lamin-A/C (LMNA, phospho Ser22) and Ras GTPase-
activating protein-binding protein 1 (G3BP1, phospho
Ser232). Briefly, equal amounts of isolated proteins from
M-4A4 and NM-2C5 cell lysates were separated by 12% SDS-
PAGE and then transferred to PVDF membrane using
Transblot (Bio-Rad). After blocking for 1 h, the membrane
was probed with rabbit polyclonal antibody against human
phospho Lamin-A/C (Cell Signaling Technology, Boston,
MA, USA) or phospho G3BP1 (Abcam, Cambridge, MA,
USA) diluted in 1:1000 overnight. After incubation with
peroxidase-conjugated goat anti-rabbit IgG secondary anti-
body (Abcam) for 1 h, immunoblots were visualized with an
enhanced chemiluminescent method kit (GE Healthcare,
Piscataway, NJ, USA). Densitometric analysis was
performed.
3 Results
Our phosphorylation profiling approach combined phospho-
peptide enrichment using TiO2 and ZrO2 particles, multistage
MS for phosphopeptide identification, and label-free spectral
counting for quantitation. Extracted proteins from the human
breast cancer cell lines M-4A4 and NM-2C5 were digested with
trypsin, and the phosphopeptides were enriched on TiO2 or
ZrO2 particles. The resulting peptide mixtures were analyzed
by online LTQ linear IT MS with two consecutive stages of
fragmentation. Automatic cross-validation by combining conse-
cutive stage MS data and the target-decoy database searching
strategy was used to identify phosphopeptides. Quantitation of
phosphoproteins in the two cell lines was achieved by the
spectral counting method, with MS2-only scan implemented
successively after each MS21MS3 scan. Sequence and site
assignments were validated with the MS21MS3 NL method.
Western blotting was used to validate the altered expression of
differentially expressed phosphoproteins (Fig. 1).
3.1 Phosphoproteome
To provide adequate coverage of the phosphoproteome, six
replicates of MS21MS3 scans for each sample were
Figure 1. Schematic illustrating the label-free quantitative
analytical approach for protein phosphorylation profiling.
Extracted proteins from human breast cancer cell lines, malig-
nant M-4A4 and non-malignant NM-2C5, were digested with
trypsin. Phosphopeptide mixtures were enriched with TiO2 and
ZrO2 particles and analyzed by LC-MS/MS. Phosphopeptides
were identified by automatic cross-validation of the MS21MS3
scans. Quantification of phosphoprotein expression in the tumor
metastasis model was implemented by spectral counting with
the MS2-only spectra. Then peptide sequence and site assign-
ments were validated by an MS21MS3 NL method. The altered
expression of selected phosphoproteins reported from spectral
counting was validated by Western blotting.
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analyzed. More than 6700 phosphopeptides were detected in
24 LC MS analyses. The six MS runs had very similar counts
of identified phosphopeptides, as shown in Fig. 2A. Only
the peptides detected three or more times within six
replicates were considered for further analysis. After
filtering with the criteria Rank’m 5 1, DCn’m Z0.1, and
the Xcorr’s Z3.7, our analysis identified 425 phosphoryla-
tion sites on 160 unique proteins with a false discovery rate
(FDR) less than 3% using the described stringent criteria in
the two cell line samples. Of these, 65 sites (15.3%) had not
been reported in the PhosphoSite Plus database as of
September, 2009 (Supporting Information Table 1). The
representative MS2 and MS3 spectra of identified peptide
VLGpSEGEEEDEALpSPAK assigned to protein DNA ligase
1 is shown in Fig. 3.
In the M-4A4 cell line, 328 phosphorylated sites on 263
unique phosphopeptides were identified, and in the NM-
2C5 cell line 345 phosphorylated sites on 264 unique
phosphopeptides were identified (Fig. 2B). Of these, we
determined the distribution between individually identified
sites to be 284 phosphoserine (pS), 43 pT, and 1 phospho-
tyrosine (pY) sites in M-4A4 cells and 297 pS, 46 pT, and 2
pY sites in NM-2C5 cells. In the Hunter and Sefton classic
study using phosphoamino acid analysis, a relative abun-
dance of 90, 10, and 0.05% for pS, pT, and pY was observed
in proliferative, non-cancerous human cells [20]. The
distribution of pS, pT, and pY sites was 86.6, 13.1, and 0.3%
Figure 2. (A) Summary of the phosphopeptide identification
counts for M-4A4 or NM-2C5 cell lines with TiO2 or ZrO2
enrichment methods in six MS21MS3 replicate runs. (B)
Identified unique phosphopeptides and phosphorylation sites
from six replicates of MS21MS3 scans of the M-4A4 and NM-
2C5 cell line samples; (C) distribution of phosphorylated sites by
amino acid; (D) GO analysis of the identified unique phospho-
proteins.
Figure 3. Representative spectra of a phosphorylated peptide
identified by automatic cross-validation of MS2 and MS3 data-
dependent NL method. (A) MS/MS spectrum of doubly charged
and doubly phosphorylated peptide VLGpSEGEEEDEALpSPAK
assigned to protein DNA ligase 1. The peak at m/z 910.6
represents the doubly charged form of the selected precursor
ion at m/z 959.8 with loss of one H3PO4 group, and at m/z 862.7
with loss of two H3PO4 groups. (B) MS/MS/MS spectrum for the
fragment ion at m/z 910.6 corresponding to NL of the H3PO4
group. The peak at m/z 862.5 represents the doubly charged
form of m/z 910.6 after loss of the H3PO4 group.
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for M-4A4 cells and 86.1, 13.3, and 0.6% for NM-2C5 cells, a
distribution markedly similar to the estimated phosphory-
lated amino acid content in the previous study (Fig. 2C).
We observed phosphorylation sites on a wide variety of
proteins. Figure 2D shows a Gene Ontology (GO) analysis of
the phosphoproteome of M-4A4 and NM-2C5 cell lines.
Almost half of the phosphorylation events occurred on
nuclear proteins, whereas only one-third of all proteins in
the IPI database are assigned as nuclear by GO [21], indi-
cating that phosphorylation in these cells preferentially
occurs in nuclear proteins. As expected, proteins annotated
as extracellular were significantly underrepresented in the
phosphoproteome. In addition, proteins annotated as
mitochondrial by GO were underrepresented, as were plas-
ma membrane proteins.
TiO2 and ZrO2 have often been used to enrich phospho-
peptides because of their strong interaction between phos-
phate groups on target molecules. We found that these two
enrichment methods were complementary in identifying
phosphopeptides, with 50–60% of identical phosphopeptides
being enriched by both TiO2 and ZrO2 (Fig. 4A). Moreover,
more selective isolation of singly phosphorylated peptides was
observed with ZrO2 compared to TiO2, whereas TiO2 prefer-
entially enriched multiply phosphorylated peptides (Fig. 4B).
3.2 Quantitative phosphoproteomics
While MS3 scans followed by each MS2 scan will interfere
with the spectral counting of peptides, we developed an
approach to address this problem whereby one MS2-only
scan is run successively after each MS21MS3 scan of the
same sample with different sample injections and different
method files. MS2-only scans in each sample were run six
times. Hierarchical clustering analysis was employed to
evaluate reproducibility between the six MS2-only scans.
Correlation factors calculated using the spectral count of
peptides showed very similar results between different MS2-
only scans in the same sample; thus, the spectral count
method is applicable in label-free shotgun proteomics
(Fig. 5). The spectral count was generated from MS2 raw
data after TPP analysis. Only the peptides detected for three
or more times in six MS2 runs for each sample were further
analyzed. After normalization for protein length, the
changed ratios and p value calculated by Student’s t-test
for each protein were recorded. As a result, 33 regulated
proteins were identified with a p value less than 0.05 from
the two enrichment methods.
Peptide sequence and site assignments reported from
MS2-only scan were validated by a MS21MS3 NL method.
Only the proteins identified both from MS2-only scans and
MS21MS3 scans were retained for further analysis. After
validation, over 70 phosphorylated sites on 27 proteins were
found to be differentially expressed, and three of them were
present in both of the enrichment experiments with the
same change trend. These included neuroblast differentia-
tion-associated protein (AHNAK), myosin-IXb, and protein
Figure 4. (A) Overlap between phosphopeptide enrichment
methods on the level of identified unique phosphopeptides in
the M-4A4 or NM-2C5 cell lines. Around 50% of the unique
phosphopeptides identified from the TiO2 method were also
identified in the ZrO2 method; (B) distribution of singly (1),
doubly (2), triply (3) and quadruply (4) phosphorylated peptides
enriched by TiO2 or ZrO2 in the two cell lines.
Figure 5. Hierarchical clustering of six MS2-only scans ofthe M-
4A4 or NM-2C5 cell samples after TiO2 or ZrO2 particle
enrichment. After MS2-only scan analysis, the RAW data file
was processed using SEQUEST and validated by TPP. Spectral
count data was then extracted from xml files. Correlation factors
were caculated from the spectral count of phosphoproteins. The
color bar represents the reproducibility between two MS2 runs
in each sample.
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NDRG1 (Supporting Information Table 2). Among the
proteins we observed, 16 proteins were expressed at higher
phosphorylation levels and 11 phosphoproteins were
underexpressed in M-4A4 cells compared with NM-2C5 cells
(Table 1). The up-regulated protein group included lamin
A/C, G3BP1, protein NDRG1, and myosin-IXb, and the
down-regulated group included AHNAK, eukaryotic trans-
lation initiation factor 5B (EIF5B), serine/threonine-protein
kinase 10 (STK10), and prostaglandin E synthase 3
(PTGES3). To provide the foundation of integrating MS21
MS3 scans and MS2-only scans, we showed that the NL peak
for the peptide AEEDEILNRpSPR assigned to the protein
calnexin was detected from both the MS2-only scan
(Fig. 6A) and the MS21MS3 scan (Figs. 6B and C).
Nevertheless, for the remaining six proteins that were not
validated by the MS21MS3 NL method, we discovered the
NL peak neither from MS2-only scans nor from MS21MS3
scans. Furthermore, we evaluated the recurrence of the
peptide AEEDEILNRpSPR in different MS21MS3 and
MS2-only scans in the same sample. The very similar
retention time of this peptide in three different MS21MS3
scans and three different MS2-only scans strongly supports
the utility of this integrated quantitative method (Fig. 7).
Although an increasing number of phospho-specific
antibodies are emerging, the availability is still limited. We
found two commercially available phospho-specific anti-
bodies for proteins from our list of differentially expressed
phosphoproteins. We used these antibodies in Western
blotting to verify the spectral counting quantification of
LMNA and G3BP1. Good agreement between the two
methods was achieved (Fig. 8).
Figure 6. Representative spectra of singly phosphorylated
peptide AEEDEILNRpSPR assigned to protein calnexin (CANX)
identified in MS2-only scan (A) and in MS21MS3 scan (B and C).
(A) In the MS2-only scan, the MS/MS spectrum shows that the
peak at m/z 706.1 represents the doubly charged form of the
selected precursor ion at m/z 754.95 with loss of one H3PO4
group. (B) In the MS21MS3 scan, the MS/MS spectrum showing
the peak at m/z 706.1 represents the doubly charged form of the
selected precursor ion at m/z 754.4 with loss of one H3PO4 group.
(C) In the MS21MS3 scan, the MS/MS/MS spectrum for the
fragment ion at m/z 706.1 corresponds to the NL of the H3PO4
group.
Figure 7. Recurrence of the same peptide in different MS2-only
and MS21MS3 scans in the same sample. Shown is the
precursor ion m/z and retention time (RT) of one identified
peptide AEEDEILNRpSPR in three different MS2-only scans
(A–C) and three different MS21MS3 scans (D–F) in the NM-2C5
cell sample enriched with ZrO2. The very similar retention time
strongly supports the utility of integrated quantitative method.
The arrow indicates the spectrum where the peptide was
identified.
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4 Discussion
In this study, we have developed a novel strategy to identify
425 phosphorylation sites on 160 unique proteins with an
FDR less than 3% in isogenic human breast cancer cell lines
M-4A4 and NM-2C5. The approach uses TiO2 and ZrO2
particle enrichment of phosphopeptides and automatic
validation by combining consecutive stage MS data and
target-decoy database searching. We have demonstrated the
comparative application of the strategy by identifying 27
phosphoproteins that were deemed to be differentially
expressed in the tumor metastasis model through spectral
counting with cross-confirmation of MS21MS3 and MS2-
only scans.
Although spectral counting approaches have been
employed for the quantitative measure of phosphoprotein
abundance by several groups, especially for differential
profiling of pY-containing proteins in cancer tissues and
cells [9], a generalizable quantitative spectral counting
method for enriched phosphoprotein analysis including
phosphoserine and pT-containing proteins has been lacking.
A remaining challenge is that MS2-only scans are often used
to implement spectral counting in label-free quantitative
proteomics. Many large-scale phosphorylation studies rely
solely on MS2 scan and report error rates o1% FDR. In
those cases, data filtering is accomplished by using high
mass accuracy data for the precursors and/or higher cutoff
values on scores derived from searching algorithms.
However, for low mass accuracy mass spectrometers, the
manual or automatic validation using the combination of
MS2 and MS3 scan is often undertaken to assure accurate
peptide and phosphorylation site assignment [13, 15, 22].
These reports indicate that cross-validation of phophopep-
tide assignment by MS2 and MS3 scans result in the high
confidence in identification [13]. Therefore, we developed an
integrated quantitative method combining spectral counting
of MS2-only scans and phosphopeptide identification
achieved with MS21MS3 scans. The phosphopeptide
sequence and site assignments reported from MS2-only
scans were validated by the MS21MS3 NL method. Only
those proteins identified by both MS21MS3 scans and with
a p value less than 0.05 in statistical analysis with spectral
counts, after normalization in MS2-only scans, can be
considered for further analysis. Finally, 27 phosphoproteins
met the criteria out of 33 proteins, where the latter group
was found to have a p value less than 0.05 by MS2-only scan.
The pitfall of this approach is that the stringent criterion
might fail to detect peptides for which MS3 are not triggered
because of low intensity (or absent) NL fragment ions, such
as pY-containing peptides.
In this study, we used the integrated strategy to identify
27 phosphoproteins that were differentially expressed in
human cells with distinct metastatic phenotypes. Of these,
16 were up-regulated and 11 were down-regulated in meta-
static M-4A4 cells relative to non-metastatic NM-2C5 cells.
The phosphorylation expression change of LMNA and
G3BP1 reported from spectral counting was validated with
good agreement by Western blotting. Using the Ingenuity
Pathways Analysis we observed that the majority of the
differentially expressed phosphoproteins were highly inter-
connected and belong to two major intracellular signaling
pathways.
Twelve of the 27 identified phosphoproteins were
revealed to be interconnected through one signaling path-
way (Fig. 9A). LMNA and G3BP1 are involved in this
pathway. They are all connected, directly or indirectly
through three signaling hub proteins, v-myc myelocytoma-
tosis viral oncogene homolog (c-myc), interferon g (IFNG),
and retinoic acid, a signal molecule involved in cellular
differentiation and response to extracellular stimuli. These
factors are well-known to influence the behavior of breast
cancer cells through multiple mechanisms, including
progression [23], inflammation [24], proliferation, and
apoptosis [25]. In another regulatory pathway, another 13 of
the identified phosphoproteins are interconnected directly,
or indirectly, through hepatocyte nuclear factor 4 a
(HNF4A) or transforming growth factor b 1 (TGFB1), a
signaling molecule that controls proliferation, differentia-
tion, and other functions in many cell types (Fig. 9B). The
interconnection between proteins identified in this study
with known cancer-associated factors implies a role for these
proteins in cancer progression or metastasis.
Lamins are components of the nuclear lamina, a fibrous
layer on the nucleoplasmic side of the inner nuclear
membrane, which is thought to provide a framework for the
nuclear envelope and may also interact with chromatin.
Functional analysis of phosphorylation sites in human
lamin A indicates the phosphorylation of T19 (Threonine),
S22, S403, and S404 in controlling lamin disassembly,
nuclear transport, and assembly [26]. In a pathogenesis
study, lamin A phosphorylation was reported to be
associated with myoblast activation and involved in the
Figure 8. Western blotting analysis of the expression of phosphoproteins LMNA and G3BP1 in M-4A4 and NM-2C5 cell line samples.
Shown in the right panel is a comparison of the six replicates of spectral counts of these phosphoproteins identified by MS/MS.
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pathogenic mechanism of Emery-Dreifuss muscular
dystrophy and limb girdle muscular dystrophy 1B [27].
Furthermore, studies have demonstrated that lamin A
Ser404 is a nuclear target of Akt phosphorylation in C2C12
cells and implicated Akt phosphorylation of lamin A in the
correct function of the nuclear lamina (Fig. 9A) [28]. The
irregularity of the nuclear envelope, whose framework is
supported by lamin, has been observed to significantly
correlate with lymph node metastases in breast cancers [29].
These findings suggest that the phosphorylation of LMNA
might play a role in the decoration of the nuclear envelope
in the cancer cell during metastasis. Our results show a
marked difference in the phosphorylation status of nuclear
lamins between the two cell lines under study. Previous
reports have shown that in some models, cells with greater
metastatic propensity display more mesenchymal properties
than their less metastatic counterparts. One such property
can be slower proliferation and cell cycle progression, which
could be reflected in a difference in the phosphorylation
state of nuclear lamins. We have previously performed
comprehensive characterization of our model [2–4] and very
little difference between proliferation rate or cell cycle
progression is observed. In fact, the metastatic cell line
M4A4 proliferates at a rate approximately 20% faster than
NM2C5 cells.
G3BP1 is an hnRNA-binding protein and an element of
the Ras signal transduction pathway. It is a DNA-unwinding
enzyme that can unwind partial RNA/DNA and RNA/RNA
duplexes in an ATP-dependent fashion. It binds specifically
to the Ras-GTPase-activating protein by associating with its
SH3 domain. In quiescent cells, G3BP1 is hyperpho-
sphorylated on serine residues, and this modification is
essential for its activity. G3BP1 harbors a phosphorylation-
dependent RNase activity, which specifically cleaves the
30-untranslated region of human c-myc mRNA (Fig. 9A)
[30]. C-myc is a multifunctional oncogene and it plays a role
in cycle progression, apoptosis, and cellular transformation.
Its overexpression is found during progression and distant
metastasis of hormone-treated breast cancer [31]. It is
possible that (de)phosphorylation of G3BP1 regulates
interaction with c-myc, supporting a role for differential
phosphorylation of this protein in the metastatic process. In
addition, the growth factor heregulin b 1 stimulation of
breast cancer cells promotes phosphorylation of G3BP1 and
increased the association of G3BP1 with GTPase-activating
protein, again suggesting a role for G3BP1 in cancer
progression [32].
5 Concluding remarks
This study describes a novel comparative phosphorylation
strategy and application of this analysis to a human cell line
model of tumor metastasis. The model consists of a pair of
monoclonal cell lines derived from the same tumor source,
but that have opposite metastatic propensity in murine
xenograft models. LC-MS/MS based spectral counting
analysis leads to the reliable identification of altered
phosphorylation events in cells of distinct phenotype. This
label-free, relative quantification of the phosphoproteome of
Figure 9. Pathway network models 1 (A) and 2 (B). A solid line indicates direct interaction; a dashed line indicates indirect interaction; a
line without arrowhead indicates binding; an arrow from protein A to protein B indicates that A acts on B. Node shapes are indicative:
triangle, kinase; diamond, enzyme; hexagon, translation regulator; trapezoid, transporter; oval (horizontal), transcription regulator; oval
(vertical), transmembrane receptor. Proteins identified in this screen are marked in shadow.
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complex samples enabled us to find new connections
between the ability of cancer cells to establish metastasis
in distant organs and altered expression levels of specific
phosphorylated proteins. Biological interpretation of our
data suggests that the phosphorylation of isoform A of
lamin A/C and GTPase activating protein binding protein 1
may be involved in the metastatic behavior of human breast
cancer. Further investigations using this strategy hold
promise for elucidating mechanisms involved in tumor
progression and identifying novel therapeutic targets for
potentially ameliorating the fatal spread of disease.
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